Skip to main content
SpringerLink
Log in

Medikamentöse Beeinflussung der Harnsäureausscheidung

  • Chapter
Hyperurikämie, Gicht und andere Störungen des Purinhaushalts

  • 43 Accesses

Zusammenfassung

Das Ziel der Behandlung der chronischen Hyperurikämie ist die dauerhafte Senkung der Serumharnsäurekonzentration in den Normalbereich, d. h. auf Werte unter 6,5 mg/dl. Diätetische Maßnahmen stellen die Basistherapie dar, die durch Medikamente ergänzt wird. Zur medikamentösen Therapie stehen zwei Substanzklassen zur Verfügung, die entweder die Harnsäurebildung hemmen (Xanthinoxidasehemmer) oder die renale Harnsäureausscheidung verbessern (Urikosurika).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arntz HR, Dreykluft HR, Leonbhardt H (1979) Wirkung Harnsäure-senkender Medikamente in niedriger Dosierung. Fortschr Med 97: 1212–1214.

    PubMed  CAS  Google Scholar 

  • Bailey RR, Reddy J (1980) Potentiation of warfarin action by sulphinpyrazone. Lancet 1: 254.

    Article  PubMed  CAS  Google Scholar 

  • Becher H (1977) Einfluß von Benzbromaron auf den Purinnukleotidstoffwechsel. Therapiewoche 27: 1126–1143.

    CAS  Google Scholar 

  • Beyer KH, Wiebelhaus VD, Tillson EK, Russo HF, Wilhoyte KM (1950) „Benemid“ p-(di-n-propylsulfamyl-)benzoic acid: inhibition of glycine conjugate reactions. Proc Soc Exp Biol Med 74: 772–775.

    PubMed  CAS  Google Scholar 

  • Bishop Ch, Rand R, Talbott JH (1951) The effect of Benemid (p-di-n-prophylsulfamylbenzoic acid) on uric acid metabolism in one normal and one gouty subject. J Clin Invest 30: 889–894.

    Article  PubMed  CAS  Google Scholar 

  • Blanchard KC, Maroske D, May DG, Weiner IM (1972) Uricosuric potency of 2-substituted analogs of probenecid. J Pharmacol Exp Ther 180: 397–410.

    PubMed  CAS  Google Scholar 

  • Bode Ch, Schuhmacher H, Goebell H, Zelder O, Pelzel H (1971) Fructose induced depletion of liver adenine nucleotides in man. Horm Metab Res 3: 289–290.

    Article  PubMed  CAS  Google Scholar 

  • Boger WP, Beatty JO, Pitts FW, Flippin HF (1950) The influence of a new benzoic acid derivative on the metabolism of paraamino-salicylic acid (PAS) and penicillin. Ann Intern Med 33: 18–31.

    PubMed  CAS  Google Scholar 

  • Boner G, Steele TH (1973) Relationship of urate and p-aminohippurate secretion in man. Am J Physiol 225: 100–104.

    PubMed  CAS  Google Scholar 

  • Bowering J, Calloway DH, Margen S, Kaufmann NA (1969) Dietary protein level and uric acid metabolism in normal man. J Nutr 100: 249–261.

    Google Scholar 

  • Brater DC (1986) Drug — drug and drug — disease interactions with nonsteroidal antiinflammatory drugs. Am J Med 80(Suppl 1A): 62.

    PubMed  CAS  Google Scholar 

  • Broekhuysen J, Pacco M, Sion R, Demenlenaese L, van Hee M (1972) Metabolism of benzbromarone in man. Eur J Clin Pharmacol 4: 125–130.

    Article  PubMed  CAS  Google Scholar 

  • Burns JJ, Yü TF, Ritterband A, Perel JM, Gutman AB, Brodie BB (1957) A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther 119: 418–426.

    PubMed  CAS  Google Scholar 

  • Burns JJ, Yü TF, Berger L, Gutmann AB (1958) Zoxazolamine. Physiological disposition, uricosuric properties. Am J Med 25: 401–408.

    Article  PubMed  CAS  Google Scholar 

  • Cartier P, Hamet M, Masbernard A. In vivo action of a hypouricemic derivate of benzofuran on purine metabolism. Unveröffentlicht, zitiert nach Heel et al. (1977).

    Google Scholar 

  • Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310: 563–572.

    Article  PubMed  CAS  Google Scholar 

  • Dantzler WH (1973) Characteristics of urate transport by isolated perfused snake proximal renal tubules. Am J Physiol 224: 445–453.

    PubMed  CAS  Google Scholar 

  • Davies-Jones GAB (1988) Anticonvulsants. In: Dukes MNG (ed) Meyler’s side effects of drugs, 11th edn. Elsevier, Amsterdam New York Oxford, pp 120–136.

    Google Scholar 

  • Dayton PG, Sicam LE, Landrau M, Burns JJ (1961) Metabolism of sulfinpyrazone (anturane) and other thio analogues of phenylbutazone in man. J Pharmacol Exp Ther 132: 287–290.

    PubMed  CAS  Google Scholar 

  • Dayton PG, Yü TF, Chen W, Berger L, West LA, Gutman AB (1963) The physiological disposition of probenecid, including renal clearance in man, studied by an improved method for its estimation in biological material. J Pharmacol Exp Ther 140: 278–286.

    PubMed  CAS  Google Scholar 

  • Delbarre F, Auscher C, Olivier JL, Rose A (1967) Traitement des hyperuricemies et de la goutte par des derives du benzofuranne. Semin Hop Paris 43: 1127–1133.

    CAS  Google Scholar 

  • Deltour G, Broekhuysen J, Ghislain M, Bourgeois F, Binon F (1967) Recherches dans la serie des benzofurannes. XXI. Effet inhibiteur de derives benzofuranniques phenoliques et de quelques analogues sur la xanthine oxidase hepatique du rat in vitro. Arch Int Pharmacodyn 161: 25–30.

    Google Scholar 

  • Diamond HS (1978) Uricosuric drugs. In: Kelley WN, Weiner JM (eds) Uric acid. Springer, Berlin Heidelberg New York, pp 459–484.

    Chapter  Google Scholar 

  • Dieterle W, Faigle JW, Moppert J (1980) New metabolites of sulfinpyrazone in man. Arzneimittelforschung Drug Res 30: 989–995.

    CAS  Google Scholar 

  • Duggan DE, Hooke KF, White SD, Noll RM, Stevenson CR (1977) The effects of probenecid upon the individual components of indomethacin elimination. J Pharmacol Exp Ther 201: 463–470.

    PubMed  CAS  Google Scholar 

  • Dukes MNG (ed) (1988) Meyler’s side effects of drugs, 11th edn. Elsevier, Amsterdam New York Oxford.

    Google Scholar 

  • Durham DS, Ibels LS (1981) Sulphinpyrazone-induced acute renal failure. Br Med J 282: 609.

    Article  CAS  Google Scholar 

  • Elion GB, Yü TF, Gutman AB, Hitchings GH (1968) Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 45: 69–77.

    Article  PubMed  CAS  Google Scholar 

  • Emmerson BT (1963) A comparison of uricosuric agents in gout, with special reference to sulphinpyrazone. Med J Aust 1: 839–844.

    Google Scholar 

  • Fanelli GM, Weiner IM (1979) Urate excretion: Drug interactions. J Pharmacol Exp Ther 210: 186–195.

    PubMed  CAS  Google Scholar 

  • Fanelli GM, Bohn DL, Reilly SS (1971) Renal urate transport in the chimpanzee. Am J Physiol 220: 613–620.

    PubMed  CAS  Google Scholar 

  • Fanelli GM, Bohn DL, Reilly SS, Weiner IM (1973) Effects of mercurial diuretics on renal transport of urate in the chimpanzee. Am J Physiol 224: 985–992.

    CAS  Google Scholar 

  • Friend DG (1968) Uricosuric drugs. Practitioner 200: 153–157.

    PubMed  CAS  Google Scholar 

  • Garcia DA, Yendt ER (1970) The effects of probenecid and thiazides and their combination on the urinary excretion of electrolytes and on acid-base equilibrium. Can Med Assoc J 103: 473–483.

    PubMed  CAS  Google Scholar 

  • Greger R (1989) Purine excretion. In: Wolfram G (ed) Genetic and therapeutic aspects of lipid and purine metabolism. Springer, Berlin Heidelberg New York, pp 71–77.

    Chapter  Google Scholar 

  • Greiling H (1969) Zur klinischen Biochemie der Gicht. Dtsch Med J 10: 336.

    Google Scholar 

  • Gross A, Girard V (1972) Über die Wirkung von Benzbromaron auf Urikämie und Urikosurie. Med Welt 23: 133–136.

    PubMed  CAS  Google Scholar 

  • Gröbner W, Zöllner N (1976) Uricosurica. In: Zöllner N, Gröbner W (Hrsg) Gicht. Springer, Berlin Heidelberg New York (Handbuch der Inneren Medizin, Bd 7/3, S 491-535)

    Google Scholar 

  • Gutman AB (1950) Uric acid metabolism and gout. Am J Med 9: 799–817.

    Article  Google Scholar 

  • Gutman AB (1965) Treatment of primary gout: The present status. Arthritis Rheum 8: 911–920.

    Article  PubMed  CAS  Google Scholar 

  • Gutman AB (1966) Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol Chemother 4: 91–142.

    Article  CAS  Google Scholar 

  • Gutman AB, Yü TF (1951) Benemid (p-(Di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians 64: 279–288.

    PubMed  CAS  Google Scholar 

  • Gutman AB, Yü TF (1957) Protracted uricosuric therapy in tophaceous gout. Lancet II: 1258–1260.

    Article  Google Scholar 

  • Gutman AB, Yü TF, Sirota JH (1955) A study by simultaneous clearance techniques, of salicylate excretion in man. Effect of alkalinization of the urine by bicarbonate administration; effect of probenecid. J Clin Invest 34: 711–721.

    Article  PubMed  CAS  Google Scholar 

  • Gutman AB, Dayton PG, Yü TF, Berger L, Chen W, Sicam IE, Burns JJ (1960) A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dog. Am J Med 29: 1017–1033.

    Article  PubMed  CAS  Google Scholar 

  • Häuselmann HJ, Studer H (1981) Antinatriuretische Wirkung von Sulphinpyrazon. Schweiz Med Wochenschr 111: 1030–1033.

    PubMed  Google Scholar 

  • Heel RC, Brogden RN, Speight TM, Avery GS (1977) Benzbromarone: A review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs 14: 349–366.

    Article  PubMed  CAS  Google Scholar 

  • Hertz Ph, Jager H, Richardson J (1972) Probenecid-induced nephrotic syndrome. Arch Pathol 94: 241–243.

    PubMed  CAS  Google Scholar 

  • Hoigné R, Malinverni R, Schopfer K (1988) Sulfonamides and miscellaneous antibacterial and antiviral drugs. In: Dukes MNG (ed) Meyler’s side effects of drugs, 11th edn. Elsevier, Amsterdam New York Oxford, pp 603–632.

    Google Scholar 

  • Kersley GD, Cook ER, Tovey DCJ (1958) Value of uricosuric agents and in particular of G-28315 in gout. Ann Rheum Dis 17: 326–333.

    Article  PubMed  CAS  Google Scholar 

  • Kippen I, Nakata N, Honda S, Klinenberg JR (1977) Uptake of uric acid by separated renal tubules of the rabbit. II. Effects of drugs. J Pharmacol Exp Ther 201: 226–232.

    PubMed  CAS  Google Scholar 

  • Koch-Weser J, Sellers EM (1976) Binding of drugs to serum albumin. N Engl J Med 294: 311–316.

    Article  PubMed  CAS  Google Scholar 

  • Kolb FO, Rukes JM (1954) Effects of benemid (probenecid) in the treatment of hypoparathyreoidism and pseudohypoparathyreoidism. J Clin Endocrinol 14: 785.

    Google Scholar 

  • Kramp RA, Lenoir R (1975) Distal permeability to urate and effects of benzofuran derivatives in the rat kidney. Am J Physiol 228: 875–883.

    PubMed  CAS  Google Scholar 

  • Krans HMJ (1988) Insulin, glycagon and oral hypoglycemic drugs. In: Dukes MNG (ed) Meyler’s side effects of drugs, 1st edn. Elsevier, Amsterdam New York Oxford, pp 889–902.

    Google Scholar 

  • Kuzell WC, Glover R, Gibbs J, Blau R (1964) Effect of anturane on serum uric acid and cholesterol in gout. A long-term study. Acta Rheum Scand (Suppl) 8: 31–40.

    CAS  Google Scholar 

  • Lee IK (1977) zitiert nach Heel et al. (1977).

    Google Scholar 

  • Löffler E, Gröbner W, Zöllner N (1983) Harnsäuresenkende Wirkung einer Kombination von Benzbromaron und Allopurinol — Untersuchungen unter standardisierten Ernährungsbedingungen. Arzneimittelforschung/Drug Res 33: 1687–1691.

    Google Scholar 

  • Masbernard A, Giudicelli CP (1981) Ten years experience with benzbromarone in the management of gout and hyperuricemia. S Afr Med J 59: 701–705.

    PubMed  CAS  Google Scholar 

  • May DC, Jarboe CH (1981) Inhibition of clearance of dyphylline by probenecid. N Engl J Med 304: 791.

    PubMed  CAS  Google Scholar 

  • May P, Lux B (1977) Gichtbehandlung und Prophylaxe mit Urikosurika. Dtsch Ärzteblatt 74: 1593–1599.

    Google Scholar 

  • McKinney SE, Peck HM, Bochey JM, Byhan BB, Schuchardt GS, Beyer KH (1951) Benemid (p-di-n-propylsulfamyl)-benzoic acid: Toxicologic properties. J Pharmacol Exp Ther 102: 208–214.

    PubMed  CAS  Google Scholar 

  • Meisel AD, Diamond HS (1977) Inhibition of probenecid uricosuria by pyrazinamide and para-aminohippurate. Am J Physiol 232: F222–F226.

    PubMed  CAS  Google Scholar 

  • Mertz DP (1969) Veränderungen der Serumkonzentration von Harnsäure unter der Wirkung von Benzbromaron. Münch Med Wochenschr 111: 491–495.

    PubMed  CAS  Google Scholar 

  • Meyboom RHB (1988) Metal antagonists. In: Dukes MNG (ed) Meyler’s side effects of drugs, 11th edn. Elsevier, Amsterdam New York Oxford, pp 461–473.

    Google Scholar 

  • Michot F, Holt NF, Fontanilles F (1981) Über die Beeinflussung der gerinnungshemmenden Wirkung von Acenocoumarol durch Sulfinpyrazon. Schweiz Med Wochenschr 111: 255–260.

    PubMed  CAS  Google Scholar 

  • Mousanabe-Puyanne A (1977) zitiert nach Heel et al. (1977).

    Google Scholar 

  • Mudge GH (1980) Inhibitors of tubular transport of organic compounds. In: Gilman A, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 929–934.

    Google Scholar 

  • Müller MM, Fuchs H, Pischek G, Bresnik W (1975) Purinstoffwechsel und Harnsäurepool bei Gichtpatienten unter Benzbromarontherapie. Therapiewoche 25: 514–520.

    Google Scholar 

  • Naftalin RJ (1970) The effects of probenecid and salicylate on uric acid flux across red cell membranes. J Physiol 211: 47P–48P.

    PubMed  CAS  Google Scholar 

  • Nenci GG, Agnelli G, Berrettini M (1981) Biphasic sulphinpyrazone-warfarin interaction. Br Med J 282: 1361–1362.

    Article  CAS  Google Scholar 

  • Nivet M, Marcovici J, Lauruelle P, Farah M (1965) Note preliminaire sur l’action d’un benzofuranne sur l’uricemie. Soc Med Hop Paris 116: 1187–1192.

    Google Scholar 

  • Nolan RP, Foulkes EC (1971) Studies on renal urate secretion in the dog. J Pharmacol Exp Ther 179: 429–437.

    PubMed  CAS  Google Scholar 

  • Ogryzlo MA, Harrison J (1957) Evalution of uricosuric agents in chronic gout. Ann Rheum Dis 16: 425–437.

    Article  PubMed  CAS  Google Scholar 

  • O’Reilly RA (1982) Phenylbutazone and sulfinpyrazone interaction with oral anticoagulant phenprocoumon. Arch Intern Med 142: 1634–1637.

    Article  PubMed  Google Scholar 

  • Pascale LR, Dubin A, Hoffman WS (1954) Influence of benemid on urinary excretion of phosphate in hypoparathyreoidism. Metabolism 3: 462–470.

    PubMed  CAS  Google Scholar 

  • Perel JM, Dayton PG, Snell MM, Yü TF, Gutman AB (1969) Studies of interactions among drugs in man at the renal level: Probenecid and sulfinpyrazone. Clin Pharmacol Ther 10: 834–840.

    PubMed  CAS  Google Scholar 

  • Persellin RH, Schmid FR (1961) The use of sulfinpyrazone in the treatment of gout. JAMA 175: 971–975.

    Article  PubMed  CAS  Google Scholar 

  • Postlethwaite AE, Gutman RA, Kelley WN (1974) Salicylate — mediated increase in urate removal during hemodialysis: evidence of urate binding to protein in vivo. Metabolism 23: 771–777.

    Article  PubMed  CAS  Google Scholar 

  • Pyörälä K, Ikkala E, Siltanen P (1963) Benziodarone (Amplivix) and anticoagulant therapy. Acta Med Scand 173: 385–389.

    Article  PubMed  Google Scholar 

  • Reynolds ES, Schlant RC, Gomick HC, Dammin GJ (1957) Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid. N Engl J Med 256: 592–596.

    Article  PubMed  CAS  Google Scholar 

  • Rizzuto VJ, Inglesby ThV, Grace WJ (1965) Probenecid (benemid) intoxication with status epilepticus. Am J Med 38: 646–648.

    Article  PubMed  CAS  Google Scholar 

  • Roch-Ramel F, Weiner IM (1980) Renal excretion of urate: Factors determining the actions of drugs. Kidney Int 18: 665–676.

    Article  PubMed  CAS  Google Scholar 

  • Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E (1978) Naproxen — probenecid interaction. Clin Pharmacol Ther 24: 706–713.

    PubMed  CAS  Google Scholar 

  • Schachter D, Manis JG (1958) Salicylate and salicyl conjugates: Fluorimetric estimation, biosynthesis and renal excretion in man. J Clin Invest 37: 800–807.

    Article  PubMed  CAS  Google Scholar 

  • Scott JT, O’Brien PK (1968) Probenecid, nephrotic syndrome and renal failure. Ann Rheum Dis 27: 249–252.

    Article  PubMed  CAS  Google Scholar 

  • Setaishi Ch, Horiuchi Y, Mashimo K (1970) Increase of urinary insulin excretion following probenecid administration in man. Endocrinol Jpn 17: 421–423.

    Article  PubMed  CAS  Google Scholar 

  • Sherry S and The Anturane Reinfarction Trial Research Group (1980) Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302: 250–256.

    Article  Google Scholar 

  • Shore PA, Brodie BB, Hogben CAM (1957) The gastric secretion of drugs: A pH partition hypothesis. J Pharmacol Exp Ther 119: 361–369.

    PubMed  CAS  Google Scholar 

  • Sinclair DS, Fox IH (1975) The pharmacology of the hypouricemic effect of benzbromarone. J Rheumatol 2: 437–445.

    PubMed  CAS  Google Scholar 

  • Singhvi SM, Duchin KL, Willard DA, McKinstry DN, Migdalof BH (1982) Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 32: 182–189.

    Article  CAS  Google Scholar 

  • Sirota JH, Yü TH, Gutman AB (1952) Effect of benemid (p-(di-n-propylsulfamyl)-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. J Clin Invest 31: 692–701.

    Article  PubMed  CAS  Google Scholar 

  • Smythe HA, Ogryzlo MA, Murphy EA, Mustard JF (1965) The effect of sulfinpyrazone (Anturan) on platelet economy and blood coagulation in man. Can Med Assoc J 92: 818–821.

    PubMed  CAS  Google Scholar 

  • Sorensen LB, Levinson DJ (1976) Clinical evalution of benzbromarone, a new uricosuric drug. Arthritis Rheum 19: 183–190.

    Article  PubMed  CAS  Google Scholar 

  • Sorensen LB, Levinson DJ (1980) Isolated defect in postsecretory reabsorption of uric acid. Ann Rheum Dis 39: 180–183.

    Article  PubMed  CAS  Google Scholar 

  • Steele TH, Rieselbach RE (1975) Renal urate excretion in normal man. Nephron 14: 21–32.

    Article  PubMed  CAS  Google Scholar 

  • Stein HB, Hasan A, Fox IH (1976) Ascorbic acid-induced uricosuria. A consequence of megavitamin therapy. Ann Intern Med 84: 385–388.

    PubMed  CAS  Google Scholar 

  • Sternon J, Kocheleff P, Couturier E, Baiasse E, Vanden-Abeele P (1967) Effet hypouricemiant de la benzbromarone — etude de 24 cas. Acta Clin Belg 22: 285–293.

    PubMed  CAS  Google Scholar 

  • Sudlow G, Birkett DJ, Wade DN (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11: 824–832.

    PubMed  CAS  Google Scholar 

  • Szczeklik A, Czerniawska-Mysik G, Nizankowska E (1980) Sulfinpyrazone and aspirin-induced asthma. N Engl J Med 303: 702–703.

    PubMed  CAS  Google Scholar 

  • Talbott JH (1957) Gout. Grune & Stratton, New York London.

    Google Scholar 

  • Talbott JH (1967) Die Gicht. Hippokrates, Stuttgart.

    Google Scholar 

  • Tester-Dalderup CBM (1988) Antiprotozoal drugs. In: Dukes MNG (ed) Meyler’s side effects of drugs, 11th edn. Elsevier, Amsterdam New York Oxford, pp 889–902.

    Google Scholar 

  • Thompson GR, Duff JF, Robinson WD, Mikkelsen WM, Galindez H (1962) Longterm uricosuric therapy in gout. Arthritis Rheum 5: 384–385.

    Article  PubMed  CAS  Google Scholar 

  • Verstraete M, Vermylen J, Claeys H (1968) Dissimilar effect of two anti-anginal drugs belonging to the benzofuran group on the action of coumarin derivates. Arch Intern Pharmacodyn Ther 176: 33–40.

    CAS  Google Scholar 

  • Vrhovac B (1988) Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG (ed) Meyler’s side effects of drugs, 11th edn. Elsevier, Amsterdam New York Oxford, pp 170–204.

    Google Scholar 

  • Walter E, Staiger Ch, de Vries J, Zimmermann R, Weber E (1981) Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol 19: 353–358.

    Article  PubMed  CAS  Google Scholar 

  • Walter-Sack I, de Vries JX, Ittensohn A, Kohlmeier M, Weber E (1988) Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klin Wochenschr 66: 160–166.

    Article  PubMed  CAS  Google Scholar 

  • Walter-Sack I, Gresser U, Adjan M, Kamilli I, Ittensohn A, de Vries JX, Weber E, Zöllner N (1990) Variation of benzbromarone elimination in man — a population study. Eur J Clin Pharmacol (in press).

    Google Scholar 

  • Weiner IM (1973) Transport of weak acids and bases. In: Orloff J, Berliner RW (eds) Handbook of Physiology, Section 8. Renal Physiology. American Physiology Society, Washington DC, pp 521–554.

    Google Scholar 

  • Weiner IM, Mudge GH (1964) Renal tubular mechanisms for excretion of organic acids and basis. Am J Med 36: 743–762.

    Article  PubMed  CAS  Google Scholar 

  • Weiner IM, Washington JA, Mudge GH (1960) On the mechanism of action of probenecid on renal tubular secretion. Bull Johns Hopkins Hosp 106: 333–346.

    PubMed  CAS  Google Scholar 

  • Weiner IM, Blanchard KC, Mudge GH (1964) Factors influencing renal excretion of foreign organic acids. Am J Physiol 207: 953–963.

    PubMed  CAS  Google Scholar 

  • Whitehouse MW, Kippen I, Klinenberg JR, Schlosstein L, Campion DS, Bluestone R (1973) Increasing excretion of urate with displacing agents in man. Ann NY Acad Sci 226: 309–318.

    Article  PubMed  CAS  Google Scholar 

  • Wingender W, Beerman D, Förster D et al. (1985) Mechanism of renal excretion of ciprofloxacin (Bay 0 9867), a new quinolone carboxylic acid derivative, in humans.

    Google Scholar 

  • Zitiert nach Hoigné et al. 1988.

    Google Scholar 

  • Witwer MW, Schmid FR, Tesar JT (1976) Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout. Br Med J 2: 89.

    Article  PubMed  CAS  Google Scholar 

  • Wyngaarden JB (1955) The effect of phenylbutazone on uric acid metabolism in two normal subjects. J Clin Invest 34: 256–262.

    Article  PubMed  CAS  Google Scholar 

  • Wyngaarden JB, Kelley WN (1983) Gout. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease, 5th edn. McGraw-Hill, New York, pp 1043–1114.

    Google Scholar 

  • Yü TF (1974) Milestones in the treatment of gout. Am J Med 56: 676–685.

    Article  PubMed  Google Scholar 

  • Yü TF (1976) Pharmacokinetic and clinical studies of a new uricosuric agent — benzbromarone. J Rheumatol 3: 305–312.

    PubMed  Google Scholar 

  • Yü TF, Gutman AB (1955) Paradoxical retention of uric acid by uricosuric drugs in low dosage. Proc Soc Exp Biol Med 90: 542–547.

    PubMed  Google Scholar 

  • Yü TF, Dayton PG, Gutman AB (1963) Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: a study of interactions between drugs. J Clin Invest 42: 1330–1339.

    Article  Google Scholar 

  • Yü TF, Perel J (1980) Pharmacokinetic and clinical studies of Carprofen in gout. J Clin Pharmacol 20: 347–351.

    Article  PubMed  Google Scholar 

  • Yü TF, Burns JJ, Gutman AB (1958) Results of clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum 1: 532–543.

    Article  PubMed  Google Scholar 

  • Yü TF, Perel J, Berger L, Roboz J, Israili ZH, Dayton PG (1977) The effect of interaction of pyrazinamide and probenecid on urinary uric acid excretion in man. Am J Med 63: 723–728.

    Article  PubMed  Google Scholar 

  • Zöllner N (1968) Die Gichtniere. In: Schwiegk H (Hrsg) Handbuch der Inneren Medizin. Bd 8/3. Springer, Berlin Heidelberg New York.

    Google Scholar 

  • Zöllner N, Gröbner W (1969) Die Wirkung von Cumarin-, Indandion-und Benzofuranderivaten auf die renale Harnsäureausscheidung. Dtsch Med Wochenschr 94: 2652–2654.

    PubMed  Google Scholar 

  • Zöllner N, Stern G, Gröbner W, Dofel W (1968) Über die Senkung des Harnsäurespiegels im Plasma durch Benzbromaron. Klin Wochenschr 46: 1318.

    Article  PubMed  Google Scholar 

  • Zöllner N, Dofel W, Gröbner W (1970 a) Die Wirkung von Benzbromaron auf die renale Harnsäureausscheidung Gesunder. Klin Wochenschr 48: 426–432.

    Article  PubMed  Google Scholar 

  • Zöllner N, Griebsch A, Fink JK (1970 b) Über die Wirkung von Benzbromaron auf den Serumharnsäurespiegel und die Harnsäureausscheidung des Gichtkranken. Dtsch Med Wochenschr 95: 2405–2412.

    Article  PubMed  Google Scholar 

  • Zöllner N, Griebsch A, Gröbner W, Hector G, Schattenkirchner M (1970 c) Klinische Erfahrungen mit dem neuen Uricosuricum Benzbromaronum. Verh Dtsch Ges Inn Med 76: 853.

    Google Scholar 

  • Zöllner N, Gresser U, Walter-Sack I (1990) Deficient Benzbromarone Elimination: A Familial Disorder? KliWo 68: 101.

    Google Scholar 

Download references

Authors
  1. W. Löffler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Poliklinik, Universität München, Pettenkoferstraße 8a, D-8000, München 2, Deutschland

    Nepomuk Zöllner

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Löffler, W. (1990). Medikamentöse Beeinflussung der Harnsäureausscheidung. In: Zöllner, N. (eds) Hyperurikämie, Gicht und andere Störungen des Purinhaushalts. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93422-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93422-3_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-93423-0

  • Online ISBN: 978-3-642-93422-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation